« Back
Home /
Human Urokinase (uPA) AssayMax ELISA Kit

Human Urokinase (uPA) AssayMax ELISA Kit

Manufacturer	Assaypro
Category	ELISA Oncology Food Safety Allergenes Drugs Proteins Neuroscience Metabolism Cholesterol & Lipid Metabolism Molecular Targets for Neuroscience Neural Signaling Neural Development
Type	Elisa-Kit
Specific against	Human
Amount	96 well plate
Item no.	EU1001-1
Approximate Leadtime	2-3 Weeks
eClass 6.1	32160605
eClass 9.0	32160605
Available
Associated Disease	Cancer
Entrez Gene	5328
Omim	191840
Swiss Prot	P00749
Unigene	Hs.77274
Description	This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.
Note	For Research Use Only
Product References	* Fujiuchi Y et al. (2003) Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol. Rep. 10(4):1001-1006 * Oka N et al. (2003) Amiloride and Urinary Trypsin Inhibitor Inhibit Urothelial Cancer Invasion. Eur Urol. 44(6):737-741 * Ueshima S et al. (2003) Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology 9:103-109 * Uchima Y et al. (2004) Inhibition and Mechanism of Action of a Protease Inhibitor in Human Pancreatic Cancer Cells.??Pancreas 29(2):123-131 * Yamaguchi Y et al. (2004) Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl, D-Arg8]-vasopressin (dDAVP). Am J Physiol Endocrinol Metab 287(5): E970-E976 * Nomuraa S et al. (2005) HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose Veins. ?European Surgical Research 37(6):370-378 * Yamaguchi Y et al. (2005) Possible Involvement of Urokinase-Type Plasminogen Activator Release From Human Peripheral Blood Lymphocytes in the Pathophysiology of Chronic Allograft Nephropathy. Transplantation Proceedings. 37(10):4276-4281 * Cederqvist K et al. (2006) High Concentrations of Plasminogen Activator Inhibitor-1 in Lungs of Preterm Infants With Respiratory Distress Syndrome. Pediatrics 117(4):1226-1234 * Yang CC et al. (2007) In vitro regulation of adipogenesis: tunable engineered tissues. J Tissue Eng Regen Med. 1(2):146-153 * Yoshida C et al. (2007) Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagulation &, Fibrinolysis. 18(5):425-433 * Ogura Y et al. (2008) Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. British Journal of Dermatology 159(1):49-60 * Ekmek?i OB et al. (2009) Effects of rhG-CSF Plus Dexamethasone on Hemostatic Parameters in Healthy Granulocyte Donors: Role of u-PA and Nitric Oxide. Clin. Appl. Thromb. Hemost. 15(6):689-694 * Okumura S et al. (2009) Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: Preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin Immunol. 130(2):175-185 * Grzmil M (2010) An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene. 29(28):4080-4089 * Rasheed SA et al. (2010) First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127(6):1475-1485 * Sutoh T et al. (2010) Nafamostat Mesilate (FUT-175) Inhibits Cell Growth and Invasion of Malignant Pleural Mesothelioma Cell Line, MSTO-211H. Hirosaki Med. J. 61:19-25 * Wyr?bska A et al. (2012) Comparison of Anti-Invasive Activity of Parthenolide and 3-Isopropyl-2-Methyl-4-Methyleneisoxazolidin-5-One (MZ-6) ? A New Compound with -Methylene--Lactone Motif ? on Two Breast Cancer Cell Lines. Chemical Biology &, Drug Design 79(1):112-120 * Vieira ML et al. (2013) Interaction of Leptospira interrogans with Human Proteolytic Systems Enhances Dissemination through Endothelial Cells and Protease Levels. Infect Immun. 81(5):1764-74. doi: 10.1128/IAI.00020-13. Epub 2013 Mar 11 * Mahmoud AE and Ali MM (2014) Fermented Pomegranate (Punica granatum) Peel Extract as a Novel Anticancer Agent Targeting Angiogenesis and Metastasis. International Journal of toxicological and pharmacological research. 6(4):60-66
Samples	Serum, Plasma, Cell Culture, Urine, Milk, Tissue Extract
Range	0.25-8 ng/ml

Note: The presented information and documents (Manual, Product Datasheet and Safety Datasheet) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.